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Abstract
Background: Dysferlin is reduced in patients with limb girdle muscular dystrophy type 2B, Miyoshi myopathy, distal
anterior compartment myopathy, and in certain Ethnic clusters.
Methods: We evaluated clinical and genetic patient data from three different Swiss Neuromuscular Centers.
Results: Thirteen patients from 6 non-related families were included. Age of onset was 18.8 ± 4.3 years. In all
patients, diallelic disease-causing mutations were identified in the DYSF gene. Nine patients from 3 non-related
families from Central Switzerland carried the identical homozygous mutation, c.3031 + 2T>C. A possible founder
effect was confirmed by haplotype analysis. Three patients from two different families carried the heterozygous
mutation, c.1064_1065delAA. Two novel mutations were identified (c.2869C>T (p.Gln957Stop), c.5928G>A
(p.Trp1976Stop)).
Conclusions: Our study confirms the phenotypic heterogeneity associated with DYSF mutations. Two mutations
(c.3031 + 2T>C, c.1064_1065delAA) appear common in Switzerland. Haplotype analysis performed on one case
(c. 3031 + 2T>C) suggested a possible founder effect.
Background
Dysferlin (DYSF) is a transmembrane protein linked to
sarcolemmal repair mechanisms. Autosomal recessive
mutations in the DYSF gene cause muscular dystrophies
(MD): a limb girdle MD, the so-called LGMD 2B, with
onset in the proximal lower limbs [1], and two distal MD,
one initially affecting the gastrocnemius muscle during
early adulthood, Miyoshi myopathy (MM) [2], and the
other involving muscles of the anterior compartment
(DMAT) [3]. Disease severity ranges from asymptomatic
mutation carriers with elevated serum CK levels [4] and
exercise intolerance [5] to severe functional disability [6].
Muscle weakness with pelvic girdle involvement on clin-
ical examination distinguishes LGMD from MM. Other
common phenotypes include a “proximo-distal” pheno-
type, characterized by simultaneous distal and proximal
weakness onset [6]. Of note, a recent MRI study suggests
that all patients have radiographic evidence of proximo-
distal muscle involvement, regardless of the clinical
phenotype [7].
The DYSF gene maps to chromosome 2p12-p14, con-
tains 55 exons and is transcribed as an 8.5 Kb major
transcript mainly expressed in skeletal and cardiac
muscles. The protein product is a 230 kDa molecule in-
volved in muscle fibre repair [8, 9]. More than 400
DYSF mutations have been described in the Leiden
muscular dystrophy database (http://www.dmd.nl);
however, a mutational hot spot has not been detected
[10–12]. Ethnic clusters have been described in Jews
from Libya [13] and the Caucasus region [14], as well
as in the Italian [15] and Spanish [16] populations.
Four mutations account for 60 % of all mutations in
Japanese patients with MM [17]. Interestingly, the type
of mutation does not correlate with phenotypic fea-
tures. In fact, the same mutation has been found to be
associated with a broad spectrum of inter—and intra-
familial clinical phenotypes [18–22].
Within this range of clinical and genetic heterogeneity,
we sought to determine frequently encountered DYSF
gene mutations and phenotypes in the Swiss population
and to uncover possible founder effects.
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Methods
Subjects
The medical records of patients of Swiss origin with pro-
gressive muscle weakness, and DYSF mutations, who were
admitted to Neuromuscular Centres in Basel, Lausanne
and Zurich between 1989 and 2015 were anonymized and
reviewed. All patients provided their written informed
consent for genetic analysis. Clinical data collected in-
cluded age and symptoms at onset, disease duration,
family pedigrees, and muscle strength according to the
Medical Research Council (MRC) scale. In addition,
CK levels, muscle biopsy and mutational analysis re-
sults were evaluated. Electromyography, electrocardi-
ography, echocardiography, pulmonary function and
muscle MRI data were reviewed when available. The
study was performed in accordance with the Declar-
ation of Helsinki and approved by the local ethics
committee (Kantonale Ethikkommission Zürich, KEK-
ZH-Nr. 2015–0036).
Genetic analysis
Sequence analysis was performed using bidirectional fluor-
escent sequencing of all 55 exons of the DYSF gene, either
in the Service de Cardiologie, Hôpital Cochin CHU Paris,
France, or at the Institute of Human Genetics, University of
Würzburg, Germany (Reference sequence: NM_003494.3).
Multiplex ligation-dependent probe amplification (MLPA)
was used in one case.
To evaluate the hypothesis that the DYSF mutation
c.3031 + 2T>C is due to a founder effect, we performed
haplotype analysis, as described previously, with 6 poly-
morphic microsatellite markers on chromosome 2p13.2
flanking the DYSF gene (D2S327, D2S2113, D2S292,
D2S291, D21S2110 and D2S2111) [23].
Results
Clinical data
Thirteen patients were included in the study. Of those, 9
patients were from three non-related families from
Central Switzerland (Canton of Schwyz). The clinical
data of 10 patients from 6 different families are sum-
marized in Tables 1 and 2. Three patients from central
Switzerland (C-6, D-10, D-11) provided blood for
haplotype analysis but refused clinical evaluation. Consan-
guinity was not reported and the parents of all patients
were healthy. Mean disease onset was in late adolescence
or early adulthood (18.7 ± 4.5 years). Early manifestations
(Table 1) included leg pain, steppage gait, Gowers’ sign
and difficulty running and jumping. Mean CK levels were
12500 ± 14400 IU/L (range 2200–46350, normal value for
our laboratory < 167 U/l, Table 1).
The clinical phenotype could be determined in 10 pa-
tients (Table 2). In all patients, the facial muscles were
spared. Four of the patients from Central Switzerland
(C-4, C-5, C-7, F-13) presented without arm weakness
a few years after the onset of symptoms (Table 2). All
patients had distal lower limb flexor weakness and 2
(C-7, F-13) also showed distal lower limb extensor
weakness. Three (C-4, C-5, C-7) patients had proximal
lower limb weakness and therefore were classified as
the “proximo-distal” (PD) phenotype [6]. Another pa-
tient (F-13) demonstrated isolated distal lower limb
weakness (foot flexion > extension) and was classified
as the MM phenotype. Three patients (C-4, C-5 and C-
7) were followed for 11, 9 and 4 years, respectively
(Table 2). All developed distal upper limb extensor
weakness with 2 (DC-4, C-7) additionally showing
distal upper limb flexor and proximal upper limb weak-
ness. Two patients from central Switzerland (C-8, D-9)
were examined 20 and 28 years after onset and demon-
strated proximal and distal upper and lower limb flexor
and extensor weakness (Table 2). Patient D-9 experi-
enced a relatively “benign” course with muscle strength
grade of at least 3 on the MRC scale (Table 2). One
patient from the Canton Thurgau (E-12) presented
7 years after onset with proximal and distal lower limb
flexor and extensor weakness, eventually developing
distal flexor and extensor and proximal upper limb
weakness (Table 2). A patient from the Canton Aargau
(B-3) presented with severe distal lower limb flexor,
proximal lower limb flexor and extensor, distal upper
limb flexor and extensor and proximal upper limb
weakness 15 years after onset. Two patients from the
Canton Fribourg were initially examined 23 (A-1) and
17 (A-2) years after onset, respectively. Patient A-1 had
generalized weakness, pronounced in the distal lower
limb extensors, and over the course of 9 years devel-
oped proximal lower and upper limb palsies. Patient A-
2 had generalized weakness, more pronounced in the
distal lower limb flexors, that progressive minimally
over 7 years. Interestingly, members of family C pre-
sented with a proximo-distal phenotype early in the
course and members of family C and patient F-13 were
notable for the lack of upper limb weakness during the
early phases of the disease. Later in the course, all pa-
tients manifested a typical LGMD phenotype; however,
the distribution of weakness was heterogeneous
(Table 2). The DMAT phenotype was not observed in
our cohort.
The use of mobility aids showed the following timeline: 2
patients required canes for walking assistance (A-1, A-2) at
the age of 35 and 49 years, respectively (disease duration
until first use of canes 12 and 21 years, respectively), and
both were eventually wheelchair-bound (17 and 24 years
after disease onset; 5 and 3 years after first cane use). Pa-
tient B-3, at age 29, 14 years after disease onset, used a
wheelchair intermittently (B-3), and patient C-8 was
wheelchair-bound, at age 43, 27 years after disease onset.
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Cardiac, pulmonary, MRI and EMG data
Electrocardiography and ECG were normal in all 9 pa-
tients who underwent examination, the longest disease
duration being 35 years (Table 1). Pulmonary function
was normal in 6 out of 7 patients, with restrictive lung
disease documented in patient A-1 (Table 1; initial pul-
monary function testing performed after 29 years of dis-
ease duration). In 3 patients, muscle MRI showed fatty
replacement of the lower limb muscles. In all three pa-
tients (A-2, E-12 and F-13), the short head of the biceps
femoris and the sartorius and the gracilis muscles were
symmetrically spared or appeared less affected than
other muscles. In patients E-12 and F-13, the semitendi-
nosus, the tibialis anterior and the extensor digitorum
longus muscles also seemed less affected, while edema
was suspected in selected lower limb muscles. In another
patient (C-7), the pelvic and the lower limb muscles ap-
peared normal. EMG was myopathic with short and
small potentials in all 8 patients examined, with spon-
taneous activity found in 5 cases (Table 1).
Pathological features and protein studies
A total of 5 surgical muscle biopsies were available
(Table 3) for evaluation. In 2 patients, biopsies were not
available because they were taken in 1986 and 1977. In 6
patients, the genetic diagnosis was made without prior
biopsy. The mean age at biopsy was 28.25 ± 13.7 years,
while the mean disease duration at biopsy was 8.3 ±
Table 1 Clinical data of Swiss dysferlinopathy patients
Family-
patient
Origin
(Canton)
Sex/age
(years)
Age at onset
(years)
Symptoms
at onset
CK level
(IU/L)
Cardiac
ultrasound/ECG
Pulmonary
function
EMG
A-1 Fribourg M/58 23 Steppage gait >2.300 normal/normal FVC 55 % n.d.
A-2 F/54 28 Difficulty walking
on tiptoes
>2.300 normal/normal normal Tibialis anterior muscle:
myopathic, fibrillations
B-3 Aargau F/33 15 Difficulty running 3.800 normal/normal normal Biceps brachii muscle:
myopathic
C-4 Schwyz M/27 17 Difficulty skiing >23.000 normal/normal normal Vastus lateralis muscle:
(downhill) and
running;
myopathic, fibrillations,
leg pain positive sharp waves
C-5 F/24 17 Difficulty walking on >15.000 normal/normal normal Tibialis anterior muscle:
tiptoes; leg pain myopathic
C-6 F/31 blood sample provided
for haplotype analysis;
consultation rejected
C-7 M/16 14 Difficulty toe walking 46.350 normal/normal normal Vastus lateralis muscle:
myopathic; positive
sharp waves
C-8 F/54 16 Leg weakness n.d. n.d. n.d. Extensor carpi radialis
muscle: myopathic
D-9 Schwyz F/45 16 Gowers’ sign >2.200 normal/normal n.d. Vastus lateralis muscle:
myopathic; fibrillations,
positive sharp waves
D-10 F/46 blood sample provided
for haplotype
D-11 M/48 analysis;
consultation rejected
E-12 Thurgau M/28 20 Difficulty jumping, >10.600 normal/normal normal n.d. (syncope during
Leg pain needle insertion)
F-13 Schwyz M/22 21 Leg weakness >9.000 normal/normal normal Gastrocnemius muscle:
myopathic; fibrillations,
positive sharp waves
M male, F female, FVC Forced vital capacity, n.d. not done, normal CK < 167 U/l. “myopathic” refers to small, short, polyphasic potentials
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9.8 years. Samples were removed from the trapezius,
quadriceps and gracilis muscles. All patients exhibited
dystrophic changes with an increased spectrum of myo-
fiber diameter and variable fibrosis. In one case with a
LGMD phenotype (B-3), striking inflammatory changes
were observed within the endomysium. Western blots
(WB) and/or immunohistochemistry (IHC) were per-
formed in 6 samples (WB only in 2 samples, IHC only
in 3 samples, WB and IHC in a single sample). On WB,
dysferlin was totally absent in all samples tested, whereas
by IHC, dysferlin was judged absent in 2 cases and re-
duced in two.
Genetic studies
Genetic data are summarized in Table 4. In 13 patients,
2 disease-causing mutations on separate alleles were identi-
fied. Nine patients from 3 non-related families from Central
Switzerland (Canton Schwyz) carried the identical splice
site mutation, c.3031 + 2T>C, 7 were homozygous (Table 4).
Three patients from 2 different families from the Can-
tons of Fribourg and Aargau carried a heterozygous
frameshift mutation c.1064_1065delAA, and 2 members
from family A, harbored the heterozygous nonsense
mutation c.2217C>A (Table 4).
Two novel mutations were identified in this patient set.
Patient C-6, who was compound heterozygous for the
c.3031 + 2T >C mutation on one allele, showed a novel mu-
tation, c.2869C>T on the other allele. Patient E-12 carried
the novel homozygous c.5928G >A mutation.
Haplotype analyses using markers flanking the DYSF
gene revealed homozygosity for at least one nearest
marker (D2S291) in all patients from the two apparently
unrelated C and D families carrying the homozygous
c.3031 + 2T>C mutation, suggesting a possible founder
mutation (See Fig. 1). In patient C-7, carrying a com-
pound heterozygous DYSF mutation (c.3031 + 2 T >C
Table 2 Phenotype of Swiss dysferlinopathy patients
Family-patient A-1 A-2 B-3 C-4 C-5 C-7 C-8 D-9 E-12 F-13
Age at onset 23 28 15 17 17 14 16 16 20 21
Age at examination/years
after onset
46/23 55/32 45/17 52/24 30/15 20/3 27/11 18 /1 26/9 15/1 18/4 44/28 36/20 27/7 31/11 21/0
Facial muscles 5/5 5/5 nd nd 5/5 5/5 5/5 5/5 5/5 5/5 5/5 5/5 5/5 5/5 5/5 5/5
Head extension 5/5 5/5 5/5 5/5 nd 5/5 5/5 5/5 5/5 5/5 5/5 4/4 nd 5/5 nd 5/5
Shoulder elevation 5/5 5/5 5/5 5/5 5/5 5/5 5/5 5/5 5/5 5/5 5/5 nd nd nd nd 5/5
External arm rotation 3/3 0/0 4+/4+ 5-/5- nd 5/5 nd nd nd 5/5 nd 0/0 nd nd nd nd
Internal arm rotation 3/3 nd nd nd nd 5/5 nd nd nd 5/5 nd nd nd nd nd nd
Arm adduction 3/3 0/0 nd nd 3/3 5/5 nd nd nd 5/5 4/4 nd nd 5/5 4+/4+ nd
Arm abduction 1/1 0/0 4+/4+ 5/5 3/3 5/5 5-/5- 5/5 5/5 5/5 4/5 0/0 4/4 5/5 4-/4- 5/5
Arm flexion nd 0/0 4+/4+ 4/4 4/4 5/5 5-/5- 5/5 5/5 5/5 4/4 0/0 4/4 5/5 4-/4- 5/5
Arm extension 1/1 1/1 4+/4+ 4+/4+ 3/3 5/5 5-/5- 5/5 5/5 5/5 4+/4+ 0/0 4/4 5/5 4/4 5/5
Wrist supination 4+/4 nd nd nd nd nd nd nd 5/5 5/5 nd nd nd nd nd nd
Wrist pronation 4+/3 3/3 4+/4+ 5/5 nd nd nd nd 5/5 5/5 nd nd nd nd nd nd
Hand flexion nd 3+/3+ 4+/4+ 5/5 4/4 5/5 5-/5- 5/5 5/5 5/5 4/4 4+/4 5-/5- 5/5 4+/4+ 5/5
Finger flexion 3/3 3-/3- 4+/4+ 4/4 4/4 5/5 5-/5- 5/5 5/5 5/5 5/5 4+/4 5-/5- 5/5 4+/4+ 5/5
Hand extension 5/5 4+/4 nd nd 4/4 5/5 5-/5- 5/5 4/4 5/5 4/4 4+/4 5-/5- 5/5 4+/4+ 5/5
Finger extension 5/5 4-/4- 5-/5- 5/5 4/4 5/5 5-/5- 5/5 4/4 5/5 4/4 4+/4 5-/5- 5/5 4+/4+ 5/5
Thumb abduction nd 4/4 4+/4+ 4+/4+ nd 5/5 nd nd nd 5/5 nd nd nd nd nd nd
Thumb extension 5/5 nd nd nd nd 5/5 nd nd nd 5/5 nd nd nd nd nd nd
Hip adduction 2/2 0/0 3/3 2+/2+ 4/4 5/5 nd 5-/5- nd 5/5 2/2 nd 4/4 nd 4+/4+ nd
Hip extension 5/5 4+/4+ 4+/4+ 4-/4- nd 4/4 4-/4- 5-/5- nd 5/5 4/4 1/1 4/4 nd 4-/4- 5/5
Knee extension 2/2 0/0 2+/2 2/2 2/2 5/5 4/4 5/5 5-/5- 5/5 4/4 3/3 3/3 5/5 4/4 5/5
Knee flexion 2/2 0/0 3+/3+ 3-/3- 2/2 5/5 4-/4- 5/5 3+/3+ 5/5 4/4 4/4 4/4 5/5 4-/4- 5/5
Foot extension 0/0 0/0 2/2 2/2 3/3 5/5 2/2 5/5 2/2 4/4 4/4 0/0 5-/5- 4/4 4/4 4/4
Toe extension 0/0 0/0 3-/3- nd nd nd nd nd nd nd nd 1/1 nd 3/3 nd nd
Foot flexion 5/5 3/3 1/1 1/1 1/1 4-/4 2/1 5-/5- 3/3 4/4 3/3 1/1 4+/4+ 4/4 4/4 3/4
Toe flexion 4+/4+ 3/3 1/1 1/1 nd nd nd nd nd nd nd 4/4 nd 4-/4- nd nd
Muscle strength grades according to Medical Research Council (MRC) scale (right/left); nd: not done
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and c.2869C>T), marker D2S291 shows a heterozygous
genotype (Fig. 1).
Discussion
Evaluation of the present cohort of 6 families brings new
genetic information about dysferlinopathy in Switzerland,
and novel data regarding a potential founder effect in
Central Switzerland. The fact that unrelated families
with identical mutations come from the same region in-
dicates that these mutations are common, and indeed,
haplotype analysis of 2 families carrying the mutation
c.3031 + 2T>C suggests a possible founder effect for
this mutation in Switzerland. The limitations of this
study are twofold: the analysis is limited by the small
cohort size and 3 out of 13 patients had not been ex-
amined clinically.
From a clinical point of view, the onset age in early adult-
hood confirms previous findings [6, 7, 24]. In addition,
late-onset [25] or congenital forms were not encountered
[26]. Three out of 4 patients from Central Switzerland pre-
sented with the PD phenotype, while another patient with
the same mutation was considered to represent the MM
phenotype. Upper limb weakness was not a presenting fea-
ture in the current cohort. Some reports suggest that the
proximo-distal phenotype occurs in up to one third of dys-
ferlinopathy cases [6]. Of note, 9 out of 10 patients devel-
oped distal upper limb weakness later in the disease course,
which has been frequently reported [27–29]. Muscle MRI
is known to reveal fatty replacement of distal and proximal
lower limb muscles in the early stages of dysferlinopathy,
including patients with clinically isolated proximal or distal
involvement [7, 30]. However, an adolescent patient with a
MM phenotype (C-7) showed a normal pelvic and whole
Table 3 Histological and biochemical data of Swiss dysferlinopathy patients
Family-patient Disease duration at biopsy (y)/muscle/findings WB Dysf/immunohistochemistry
A-1 26/trapezius/atrophic fibers; slight fibrosis; fatty infiltration absent/nd
A-2 Biopsy in 1986; histopathological data na absent/nd
B-3 1/vastus lateralis/atrophic fibers; fibre size variability;/re- and degenerating fibers;
necrotic fibers; endo- and perimysial fibrosis; inflammation
absent/reduced
C-4 3/vastus lateralis/de- and regenerating fibers, nd/absent
whorled fibers, myophagocytosis, endomysial fibrosis
C-5 to C-7 Genetic testing without prior biopsy
C-8 Biopsy in 1977; na
D-9 20/vastus lateralis/focal fiber atrophy, hypertrophy, nd/reduced
necrotic fibers, increased internalized nuclei
D-10, D-11 Genetic testing without prior biopsy
E-12 1/gracilis/re- and degenerating fibers, nd/absent
myophagocytosis, fibrosis, COX-neg. fibers
F-13 Genetic testing without prior biopsy
Nd not done, WB Dysf result of the presence or absence of dysferlin by Western-blot analysis
Table 4 Dysferlin mutations in Swiss patients
Family-patient Exon/Intron DNA Effect of mutation
A-1 ex12 c.1064_1065delAA p.Lys355ArgfsX4
ex23 c.2217C>A p.Tyr739X
A-2 ex12 c.1064_1065delAA p.Lys355ArgfsX4
ex23 c.2217C>A p.Tyr739X
B-3 ex12 c.1064/1065delAA p.Lys355ArgfsX4
ex25-27 Deletion exon 25-27
C-4 IVS28 c. 3031 + 2T>C Abn. Spli.
IVS28 c. 3031 + 2T>C Abn. Spli.
C-5 IVS28 c. 3031 + 2T>C Abn. Spli.
IVS28 c. 3031 + 2T>C Abn. Spli.
C-6 IVS28 c. 3031 + 2T>C Abn. Spli.
ex27 c. 2869C>T p.Gln957X
C-7 IVS28 c. 3031 + 2T>C Abn. Spli.
IVS28 c. 3031 + 2T>C Abn. Spli.
C-8 IVS28 c.3031 + 2T>C Abn. Spli
IVS28 c.3031 + 2T>C Abn. Spli
D-9 IVS28 c. 3031 + 2T>C Abn. Spli.
IVS28 c. 3031 + 2T>C Abn. Spli.
D-10 IVS28 c. 3031 + 2T>C Abn. Spli.
IVS28 c. 3031 + 2T>C Abn. Spli.
D-11 IVS28 c. 3031 + 2T>C Abn. Spli.
IVS28 c. 3031 + 2T>C Abn. Spli.
E-13 Ex53 c.5928G>A p.Trp1976Stop
Ex53 c.5928G>A p.Trp1976Stop
F-13 IVS28 c. 3031 + 2T>C Abn. Spli.
IVS28 c. 3031 + 2T>C Abn. Spli.
Novel mutations appear in bold; Ex exon, IVS intervening sequence
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lower limb muscle MRI, similarly to a patient described
with isolated hyperCKemia [31].
Interestingly, we found clinical phenotype variability
within families and within unrelated carriers with similar
mutations. Such variability has already been reported in
Libyan Jews [13] and was found to be particularly
relevant in a 6-generation, highly consanguineous family
originating from an isolated village in Dagestan [32]. This
observation may indicate that to date, unknown genetic or
environmental modifiers play a role in influencing the
clinical phenotypes of the mutated DYSF gene [22].
Accordingly, it would be interesting to study micro-RNAs
Fig. 1 Haplotype Analysis. Haplotype analysis using six microsatellite markers flanking the DYSF gene in families C and D. The DYSF gene is
located between markers D2S292 and D2S291. In all patients carrying the homozygous c.3031 + 2T>C mutation, the adjacent marker D2S291 also
shows a homozygous genotype (allele 178) suggesting that this mutation may be a founder mutation in these two families. Accordingly,
in patient C-6 carrying a compound heterozygous DYSF mutation (c.3031 + 2T>C and c.2869C>T), the marker D2S291 shows a heterozygous
genotype (278–290)
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known to be involved in many biological processes, in-
cluding epigenetic changes. Other cardinal features of our
cohort were very high CK levels, as previously described
[7], the absence of cardiac impairment (nevertheless
encountered in few patients [6, 25, 33, 34] and present in
a knock out mouse model [35]), and the risk of developing
respiratory failure late in the disease course [36, 37], as
observed in one of our patients.
EMG showed myopathic changes and pathologic spon-
taneous activity. In one case, the biopsy revealed striking
endomysial inflammation, in line with frequently observed
inflammatory changes in dysferlinopathy and other mus-
cular dystrophies [18, 38]. Immunosuppressive treatment,
however, fails to improve muscle weakness [39]. It has
been postulated that dysferlin may be linked to membrane
repair and/or inflammatory activation [40], and in a few
cases, splice site mutations disrupting dysferlin are known
to produce inflammation [18]. Conversely, most of our
patients with splice mutations showed no evidence of
inflammation on muscle biopsy, indicating the lack of
clear correlation between inflammation and genotype. On
Western blot (WB) 3 cases showed a consistent reduction
in dysferlin, as has been previously described [41].
In dysferlinopathies, genotype is not predictive of dis-
ease severity, and genotype-phenotype correlations are
not clear-cut [15, 42]. However, correlation has been
found between certain geographical areas and the age of
onset, notably in Japanese and Italian MM patients [17],
who develop symptoms earlier than patients with LGMD
2B [10]. The most severely affected patients in our study
(Patients A-1 and A-2, described previously [12]) carried
the truncating mutation c.2217C>A (p.Tyr739X) with a
disease duration of 17 and 24 years, respectively, before
the patients became wheelchair-bound. One of the older
patients (C-8), carrying the c.3031 + 2T>C homozygous
mutation, became wheelchair bound after a disease
duration of 27 years, and patient D-9 showed rela-
tively mild impairment 20 years after onset. However,
in all other patients carrying this mutation, disease
duration was shorter; thus precluding longitudinal
comparisons. A longer follow-up is necessary to assess
the onset and time-course of the various disabling
symptoms.
Conclusion
Our study confirms the broad phenotypic heterogeneity,
often accompanied by markedly elevated CK levels, asso-
ciated with DYSF mutations in the Swiss population.
Due to a potential founder effect in the past, two muta-
tions appear to be endemic in central Switzerlans. These
findings are important for genetic counselling and should
facilitate targeted molecular diagnosis of dysferlin defi-
ciency in patients of Swiss origin.
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